VidaMed shareholders file complaint over Medtronic deal
This article was originally published in Clinica
VidaMed has rejected accusations, believed to be filed by its shareholders, concerned with its recently-announced plans to be bought by Medtronic. The Fremont, California company says the complaints include breach of fiduciary duty by its directors in relation to the proposed merger. Three complaints have been filed against the company, its directors and Medtronic. VidaMed will defend its position.
You may also be interested in...
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.
Aker BioMarine seeks supplement firms to use its EPA/DHA innovation bound by lysophosphatidylcholine to enable the fatty acids to pass through the blood-brain and blood-retinal barriers and boost of eye and brain health benefits. It will submit an NDI notificaion in the US during 2022.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.